Purpose: The standard for generalized epilepsies (GE) monotherapy in treatment is valproic acid (VPA) and lamotrigine (LTG) has been proposed as an alternative to VPA. This study aimed to evaluate the safety and efficacy of LTG on GE seizure in comparison with VPA. Method: A search was conducted based on the databases from Pubmed, Embase and the Cochran database up to February 2017. The relative risk odds ratios (ORs) and the relevant 95% confidence intervals (CI) were determined. Results: Five randomized controlled trials and four observational cohort studies involving 1732 cases were included. The results indicated that VPA was significantly superior to LTG for the outcome rate to treatment withdrawal for any reason and seizure freedom. The ORs and 95% CI of VPA versus LTG for withdrawal after 12-and 24-month treatment were 0.39(0.27, 0.56) and 0.50(0.14, 1.75), respectively, and were 3.51(2.68, 4.59) and 8.58(5.40, 13.63)for 12-and 24-month seizure free intervals, respectively. Moreover, the risk of adverse effects (OR (95%CI); 1.11(0.61-2.01)) was not significantly different between the two groups. However, the treatment withdrawal due to lack of seizure control were in the LTG group (OR (95%CI); 0.15(0.10-0.23)), while the treatment withdrawal due to intolerable side effects were in the VPA group (OR (95%CI); (1.75(1.10-2.80)).
Introduction
Epilepsy influences 65 million people worldwide and entails a major burden in seizure-related disability, stigma, mortality, and costs [1, 2] . Around 30-40% of patients have seizures that are generalized at onset. In general, generalized epilepsies (GE) are determined and affect otherwise normal people of both sexes and races [3] . Besides, GE was characterized by widespread involvement of bilateral cortical regions at the onset. They are usually accompanied by impairment of consciousness, which can further be divided into clonic, tonic, absence, atonic, tonic-clonic and myoclonic seizure types [4] .
The goal in the first line pharmacologic management of epilepsy is monotherapy due to it is effective, well tolerated and associated with low costs, higher quality of life as well as better patient compliance. A long-term (up to 6 years) un-blinded study was designed by The Standard and New Antiepileptic Drugs (SANAD) trial, which declared that valproic acid (VPA)was identified as a first-line treatment for patients diagnosed with generalised-onset seizures [5] . VPA is a very effective anticonvulsant drug for GE, yet it carries some risks connected with its side effects profile [6, 7] . Particularly for women of childbearing age, VPA was concerned about higher rates of teratogenicity and delayed cognitive development in children in utero. Taking it into consideration, lamotrigine(LTG) has been suggested as an alternative to VPA [8] . LTG has been proposed as first line new AED in treating childhood absence, juvenile absence, juvenile myoclonic and generalized tonic-clonic epilepsy according to National Institute for Health and Care Excellence (NICE) guidelines [9] . LTG is a phenyltriazine derivative which acts through inhibition of voltage-activated sodium channels and possibly calcium channels, preventing the release of glutamate [10] . Besides, LTG is also effective in controlling absence seizures and generalized tonicclonic seizures [11, 12] . Nevertheless, there are some reports of myoclonic seizure exacerbation [13] .
Although conventional anti-epileptic drug VPA and the modern LTG are identified as optimal first line or second-line monotherapy for GE, effectiveness and course of treatment vary between the patients and still remain a matter of discussion [7, 9, 14] . In 2007, Tudur Smith et al. [15] performed a meta-analysis to compare AEDs for different types of epilepsy. However, they included only one study to compare VPA with LTG. Their result might be not robust. Therefore, we conducted a meta-analysis of published trials through comparing VPA with LTG to evaluate the effect on total withdrawal rate, the seizure-freedom rate, and adverse events in patients with GE.
Methods

Search strategy
The following electronic databases were searched till February 2017 such as Pubmed, Embase and the Cochrane database. The electronic search strategy included the terms, respectively, epilepsy; seizure; myoclonic epilepsy; absence epilepsy; tonicclonic epilepsy; clonic epilepsy; tonic epilepsy; atonic epilepsy; generalised epilepsies; lamotrigine; valproate and valproic acid. Studies only in English were retrieved. Two authors reviewed the titles and abstracts of articles obtained from electronic databases respectively. If the abstract was relevant to this study, we read the full text and decided which articles were eligible for full-text review and disagreement was settled by mutual discussion.
Inclusion and exclusion criteria
Inclusion criteria were: (i) comparative study(randomized controlled trial (RCT), cohorts, case-controls and observational studies), (ii) investigated GE patients, (iii) the study compared VPA to LTG(iv) reported the number of outcome events in different interventions. The aim was to include only RCTs in the analysis. However, due to their paucity, other intervention studies and observational studies were included among which RCTs and observational studies were analyzed separately in subgroup for the reason that direct comparison between the estimates of observational studies and RCTs might be misleading. Exclusion criteria were shown as follows(i) review articles, meta-analysis, and guidelines, (ii) unavailability of a medical treatment comparison group, (iii) studies with no LTG arm, (iv) seizure data was not reported.
Data extraction
Two reviewers independently extracted the data. In case of disagreement between the two reviewers, a third reviewer extracted the data. The following information was extracted from the trails including the name of first author; country of origin; patients' characteristics (mean age, gender) as well as operational definitions and outcomes. For dichotomous outcomes, the number of participants experiencing the outcome and the number assessed in each treatment group were pointed out. When information was missing, we attempted to contact the primary author via email to seek clarification.
Studied outcomes
The following outcomes relevant to the efficacy of VPA versus LTG were collected: (1) Proportion of patients with treatment withdrawal for any reason; (2) Proportion of patients achieving seizure freedom; (3) Proportion of patients with adverse effects.
Quality assessment
To evaluate the risk of bias in the included RCTs, two authors independently assessed the quality of each trial through using the Cochrane Collaboration's tool. The following domains were assessed including selection bias, attrition bias, performance and detection bias, reporting bias, and other bias. The Newcastle--Ottawa Scale (NOS) was used to evaluate the quality of nonrandomized studies, discriminating between case-control trials and cohort studies. The NOS was a scale recommended by the Cochrane Non-Randomized Studies Methods Working Group. When analyzing case-control trials, NOS addresses three areas including selection, comparability and exposure, while it includes selection, comparability and outcome in cohort studies [16] . A quality score of 0-9 points was allocated to each nonrandomized study. RCTs with low risk of bias and nonrandomized studies achieving 7 points were considered to be of high quality. This scale was developed for application in systematic reviews and meta-analyses.
Statistical analysis
Dichotomous variables were respectively analyzed by odds ratios. Odds ratios (ORs) for binary outcomes were chosen due to be associated with less heterogeneity in meta-analysis than risk differences or relative risks [17] . Cochran's Q-statistic test was applied to access between-study heterogeneity and I 2 were used to test for heterogeneity between the included studies (P < 0.05 is considered for significant heterogeneity). The random effects model results were used if there was evidence for heterogeneity between studies because it provides a more conservative effect than the fixed-effects model [18] . If heterogeneity was found, we performed sensitivity analysis through eliminating one study at a time checking for resolution of heterogeneity. Publication bias was assessed by the visual funnel plot [19] . Data were analyzed based on the use of the Review Manager (RevMan version 5.3; Cochrane Collaboration, Oxford, UK).
Result
Study selection
A total of 657 potential trials were identified through using the first search strategy. A diagram summarizing the process of study selection is shown in Fig. 1 . After applying the selection criteria, five RCTs [20] [21] [22] [23] [24] and four cohort studies [10, [25] [26] [27] were identified in the final analysis.
Characteristic of trials
Together, identified studies enrolled a total of 1732 patients and included studies were published between 2003and 2016. Duration of follow-up ranged from 1 to24 months. The detail information was summarized in Table 1 . The risk of bias of the RCTs included in this meta-analysis is summarized in Fig. 2 . Although most studies had a low risk of bias, only one study did have an unclear risk. Among the studies, the risk of bias was assessed to be low. After the use of NOS to evaluate the quality of nonrandomized studies, four nonrandomized studies were considered being of high quality (Table 2 ).
Treatment withdrawal for any reason
Data of six trials [20] [21] [22] 24, 26, 27] was available on treatment withdrawal for12 months including 747 patients. The pooled estimated OR was 0.39 (95%CI: 0.27-0.56), favoring VPA (P < 0.01). Moreover, there was no significant heterogeneity among the identified studies evaluating mortality (I 2 = 5%, P = 0.38). In the subgroup analysis, the results were also robust in RCT and cohort groups. (Fig. 3A) As for treatment withdrawal for 24 months, all two trials [26, 27] were included. The estimates of pooled OR was 0.40 (95% CI: 0.24-0.68), favoring VPA (P < 0.01), yet with significant heterogeneity (I 2 = 76%, P = 0.04). After using the random effects model, the result presented no significant differences between the VPA and LTG groups (OR, 0.50; 95% CI 0.14-1.75; P = 0.28). (Fig. 3B ) Fig. 2 . Quality assessment of the included RCTs using the Cochrane risk of bias assessment. The most common reasons for treatment withdrawal were lack of seizure control and intolerable side effects. We performed a subgroup meta-analysis that was stratified by lack of seizure control and intolerable side effects. Outcomes are shown in Fig. 3C and D. Due to lack of seizure control, the majority of the patients with treatment withdrawal were in the LTG group (OR, 0.15; 95% CI 0.10-0.23; P < 0.01).The largest percentage of the subjects discontinuing due to intolerable side effects were in the VPA group (OR, 1.75; 95% CI 1.10-2.80; P = 0.02).
Seizure freedom
Information on seizure-free intervals for 12 months was available for 1383 patients in six trials [10, [20] [21] [22] 25, 26] . The outcomes demonstrated that VPA cure was superior to LTG (OR, 3.51; 95% CI 2.68 to 4.59, P < 0.01). There was no significant heterogeneity (I 2 = 29%, P = 0.22).In the subgroup analysis, the results were also robust in RCT and cohort groups (Fig. 4A) . Three studies [10, 23, 27] including 991 participants, reported seizure-freedom for 24 months. The outcomes showed that VPA cure was still superior to LTG (OR, 8.58; 95% CI 5.40-13.63, P < 0.01). There was no significant heterogeneity (I 2 = 0%, P = 0.70).
Besides, in the subgroup analysis, the results were also robust in RCT and cohort groups (Fig. 4B) .
Adverse effects
Sedation, tremor, weight gain and hair loss were among the four most common adverse effects in VPA group. Headache, skin rash, nervousness and dizziness were most common recorded in patients taking LTG. Eight trials [20] [21] [22] [23] [24] [25] [26] [27] reported the incidence of overall adverse events in the VPA group and LTG group. However, there was no significant difference between VPA and LTG groups (OR = 1.11; 95% CI = 0.61-2.01; p = 0.73).Besides, the heterogeneity between trials was moderate (I 2 = 63%, P = 0.008). In the subgroup analysis, the results did not show difference in RCT and cohort groups (Fig. 5 ).
Subgroup meta-analysis
Considering that the evidence acquired from these RCTs showed high reliability, we performed a subgroup meta-analysis that was stratified by RCTs. RCTs and non-randomized studies presented the same results for the overall OR estimate for treatment withdrawal, seizure freedom and adverse effects (Table 3) .
Sensitivity analysis and publication bias
The sensitivity analysis was performed by randomly excluding one trial and interchanging fixed-effects and random-effects models from pooled analysis, which confirmed the outcomes of being stable.
Publication bias was assessed by funnel plots and Egger's test. According to Fig. 6 , the shape of funnel plot did not reveal an indication of obvious asymmetry. In addition, we used Egger's test to provide statistical evidence of funnel plot symmetry and the results did not show any proof of publication bias.
Discussion
This meta-analysis of five RCTs and four nonrandomized cohort studies, all of which included a total of 1732 patients through comparing the efficacy of the VPA and the LTG as optimal first line monotherapy for GE. Results demonstrated that VPA was significantly superior to LTG for the outcome rate to treatment withdrawal for any reason and seizure freedom. Moreover, there was no difference between treatment groups regarding analysis adverse effects. Sensitivity analysis indicated that the findings are robust and not affected by publication bias.
For the treatment of the GE, VPA was the conventional antiepileptic drug of choice. It is widely considered as the treatment of choice for generalized epilepsies or difficult-toclassify seizures [5] . In SANAD, VPA was more efficacious than LTG. The guidelines were equal to our findings. Based on our analysis, we concluded that VPA appeared to be more effective for 12-month and 24-monthseizure freedom. Moreover, we found that VPA leads to lower treatment withdrawal for 12-month and 24-monthin comparison with LTG. Besides, the present study findings are consistent with studies [5, 24, 28] .
In addition, lack of seizure control and intolerable side effects were the most common reasons for treatment withdrawal. Principal reason of earlier discontinuation of therapy in LTG group was referred to lower efficacy in comparison with VPA group. The largest percentage of the subjects discontinuing due to intolerable side effects were in the VPA group. As the adverse event profile of the drug is often a major determinant in the choice of therapy, long-term tolerability of AEDs in patients is important, [29] . VPA had the widest range of side-effects, including weight gain, hair loss, gynaecomastia and sedation and relatively fewer different side-effects were reported for LTG. However, there was no significant difference between treatment groups in terms of analysis adverse effects. This result was inconsistent with metaanalysis by Brigo et al. [30] . They demonstrated that more adverse events occurred in the VPA group. However, their analysis included only one RCT and absence seizures in children.
Although VPA is the AED of choice in most clinical practice guidelines for GE, it is associated with teratogenic and adverse esthetic effects (obesity, hirsutism, alopecia) that have an especially negative impact on young women [31, 32] . The International League Against Epilepsy (ILAE) and European Academy of Neurology (EAN) joint taskforce discouraging the use of VPA in women and girls unless other treatments fail [7] . Besides, the ILAE-EAN taskforce also advocate considering a switch away from VPA if a female patient established on treatment wished to consider pregnancy. In addition, LTG was reported as a safe and effective treatment option for GE from monotherapy trials [33, 34] . However, Nicolson et al. [10] suggested that when VPA fails because of lack of efficacy, switchover to LTG is unlikely to be successful and a second antiepileptic drug should be added in this situation. Moreover, two reviews also recommend LTG to female, especially in pregnancy. Weston et al. [35] found that the children exposed to VPA were at a higher risk of malformation compared with children born to women without epilepsy and to women with untreated epilepsy. There was no increased risk for major malformation for LTG. Moreover, Bromley et al. [36] demonstrated that the intelligence quotient (IQ) of children exposed to VPA was lower than for children born to women without epilepsy. Also, IQ was significantly lower for children exposed to VPA versus LTG. If, however, VPA fails because of adverse effects, then it is appropriate to switch to an alternative antiepileptic drug.
There are several potential limitations of our analysis. Firstly, unpublished studies were not included because of the difficulty in accessing their data even though no evidence of publication bias in the results was obtained. Secondly, for the reason that most of the studies reported that the doses used were the therapeutic dose range of the AEDs, it was impossible to assess tolerability by different doses. However, it is known that most of the adverse effects are dose dependent. Thirdly, the result of adverse effects in this study might be not accurate because there are few studies and they employ different methodologies [10, 23, 25] . Methodologies bias could exist, since dosing was left to the physician's usual practice and lower doses of VPA were used in females [23] . In addition, women were more likely to receive LTG as first line treatment, although it is unlikely to have affected the outcome [10] . The analysis of the outcome of adding or switching over to LTG from VPA is consistent with LTG being less effective [25] . Additionally, one included study was the lack of description of the blinding of participants and the blinding of outcome assessors; which were due to the nature of the intervention. To conclude, this meta-analysis shows that VPA generally appears to be a better choice in controlling seizure following GE. Moreover, therapy should be switched to alternative monotherapy if an adequate trial of VPA monotherapy is not effective and intolerable. To make any practical recommendations, major double-blind, RCTs for evaluating the safety, efficacy and quality of life of patients following GE are required, especially in women and girls.
